Replimune Group Key Executives
This section highlights Replimune Group's key executives, including their titles and compensation details.
Find Contacts at Replimune Group
(Showing 0 of )
Replimune Group Earnings
This section highlights Replimune Group's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
$10.45
Stock Price
$804.80M
Market Cap
331
Employees
Woburn, MA
Location
Financial Statements
Access annual & quarterly financial statements for Replimune Group, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $2.65M | $2.45M | $4.58M | $4.14M | $1.81M |
| Gross Profit | $-2.65M | $-2.45M | $-4.58M | $-4.14M | $-1.81M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $174.96M | $126.53M | $79.55M | $56.75M | $38.76M |
| General and Administrative Expenses | $- | $- | $- | $23.20M | $17.44M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $59.81M | $50.55M | $38.77M | $23.20M | $17.44M |
| Other Expenses | $- | $-5.68M | $-1.06M | $-665.00K | $-16.00K |
| Operating Expenses | $234.77M | $174.17M | $115.14M | $77.15M | $53.11M |
| Cost and Expenses | $234.77M | $174.17M | $115.14M | $77.15M | $53.11M |
| Interest Income | $16.70M | $10.01M | $390.00K | $916.00K | $2.42M |
| Interest Expense | $- | $4.16M | $2.22M | $3.06M | $1.92M |
| Depreciation and Amortization | $2.65M | $2.45M | $4.58M | $4.14M | $1.81M |
| EBITDA | $-230.20M | $-170.30M | $-114.41M | $-76.48M | $-52.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-234.77M | $-177.08M | $-118.31M | $-79.95M | $-56.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $19.39M | $3.08M | $278.00K | $-915.00K | $3.57M |
| Income Before Tax | $-215.39M | $-174.00M | $-118.04M | $-80.87M | $-52.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $408.00K | $288.00K | $1.16M | $2.40M | $1.90M |
| Net Income | $-215.79M | $-174.28M | $-118.04M | $-80.87M | $-52.62M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-3.24 | $-2.99 | $-2.26 | $-1.75 | $-1.54 |
| EPS Diluted | $-3.24 | $-2.99 | $-2.26 | $-1.75 | $-1.54 |
| Weighted Average Shares Outstanding | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M |
| Weighted Average Shares Outstanding Diluted | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $4.04M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $736.00K | $655.00K | $700.00K | $700.00K | $621.00K | $528.00K | $1.29M | $1.22M | $1.23M | $1.16M | $1.16M | $1.14M | $1.12M | $1.10M | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-736.00K | $3.39M | $-700.00K | $-700.00K | $-621.00K | $-528.00K | $-1.29M | $-1.22M | $-1.23M | $-1.16M | $-1.16M | $-1.14M | $-1.12M | $-1.10M | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 83.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $48.00M | $43.45M | $42.97M | $42.58M | $42.85M | $49.10M | $40.44M | $37.95M | $30.26M | $28.83M | $29.48M | $21.74M | $19.35M | $19.90M | $18.55M | $16.23M | $14.32M | $14.05M | $12.16M | $11.19M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $12.74M | $11.40M | $- | $10.35M | $9.35M | $8.83M | $5.96M | $5.95M | $5.61M | $5.68M | $5.20M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $18.02M | $15.47M | $14.39M | $16.18M | $13.69M | $14.73M | $15.21M | $15.04M | $11.37M | $12.74M | $11.40M | $10.25M | $10.35M | $9.35M | $8.83M | $5.96M | $5.95M | $5.61M | $5.68M | $5.20M |
| Other Expenses | $- | $- | $- | $-536.00K | $1.34M | $-1.41M | $1.37M | $-1.15M | $147.00K | $-2.66M | $-2.02M | $-210.00K | $-241.00K | $-356.00K | $-252.00K | $334.00K | $-454.00K | $-517.00K | $-28.00K | $-26.00K |
| Operating Expenses | $66.02M | $58.92M | $56.93M | $58.09M | $56.12M | $63.39M | $55.26M | $52.11M | $41.02M | $41.01M | $40.02M | $31.06M | $28.96M | $28.52M | $26.59M | $21.37M | $19.73M | $18.91M | $17.15M | $15.49M |
| Cost and Expenses | $66.02M | $58.92M | $57.37M | $58.09M | $56.12M | $63.39M | $55.26M | $52.11M | $41.02M | $41.01M | $40.02M | $31.06M | $28.96M | $28.52M | $26.59M | $21.37M | $19.73M | $18.91M | $17.15M | $15.49M |
| Interest Income | $- | $- | $- | $- | $5.69M | $6.05M | $6.19M | $5.88M | $2.67M | $1.11M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $1.98M | $1.97M | $1.96M | $1.95M | $1.55M | $1.50M | $1.66M | $1.57M | $1.49M | $550.00K | $552.00K | $553.00K | $555.00K | $557.00K | $558.00K | $560.00K | $807.00K | $848.00K | $845.00K | $890.00K |
| Depreciation and Amortization | $993.00K | $925.00K | $736.00K | $705.00K | $675.00K | $654.00K | $621.00K | $528.00K | $1.29M | $1.22M | $1.23M | $1.16M | $1.16M | $1.14M | $1.12M | $1.10M | $401.00K | $425.00K | $391.00K | $342.00K |
| EBITDA | $-62.79M | $-50.16M | $-51.51M | $-53.20M | $-48.81M | $-58.49M | $-47.47M | $-47.74M | $-37.52M | $-41.58M | $-40.88M | $-30.91M | $-28.70M | $-28.38M | $-26.42M | $-20.65M | $-20.52M | $-18.97M | $-16.34M | $-14.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1432.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-66.02M | $-58.92M | $-57.37M | $-58.76M | $-56.54M | $-63.83M | $-55.65M | $-52.99M | $-41.63M | $-41.58M | $-40.88M | $-31.99M | $-29.70M | $-29.25M | $-27.38M | $-22.18M | $-20.27M | $-19.66M | $-17.83M | $-16.39M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1453.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $254.00K | $5.86M | $3.60M | $3.62M | $5.89M | $3.59M | $6.29M | $4.04M | $1.94M | $-1.52M | $-1.38M | $292.00K | $24.00K | $-108.00K | $70.00K | $685.00K | $-1.51M | $-432.00K | $340.00K | $596.00K |
| Income Before Tax | $-65.77M | $-53.05M | $-53.77M | $-55.14M | $-50.65M | $-60.24M | $-49.35M | $-48.95M | $-39.69M | $-43.10M | $-42.25M | $-31.70M | $-29.67M | $-29.36M | $-27.31M | $-21.50M | $-21.78M | $-20.09M | $-17.49M | $-15.79M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1364.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $575.00K | $- | $- | $-65.00K | $473.00K | $-201.00K | $201.00K | $712.00K | $1.64M | $-2.11M | $-1.47M | $343.00K | $314.00K | $201.00K | $306.00K | $894.00K | $353.00K | $331.00K | $817.00K | $864.00K |
| Net Income | $-66.34M | $-53.05M | $-53.77M | $-55.08M | $-51.12M | $-60.04M | $-49.55M | $-49.24M | $-39.69M | $-43.10M | $-42.25M | $-31.70M | $-29.67M | $-29.36M | $-27.31M | $-21.50M | $-21.78M | $-20.09M | $-17.49M | $-15.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1362.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.79 | $-0.68 | $-0.78 | $-0.90 | $-0.77 | $-0.90 | $-0.75 | $-0.87 | $-0.69 | $-0.79 | $-0.78 | $-0.67 | $-0.57 | $-0.56 | $-0.53 | $-0.46 | $-0.44 | $-0.46 | $-0.44 | $-0.41 |
| EPS Diluted | $-0.79 | $-0.68 | $-0.78 | $-0.90 | $-0.77 | $-0.90 | $-0.75 | $-0.87 | $-0.69 | $-0.79 | $-0.78 | $-0.67 | $-0.57 | $-0.56 | $-0.53 | $-0.46 | $-0.44 | $-0.46 | $-0.44 | $-0.41 |
| Weighted Average Shares Outstanding | 83.50M | 78.57M | 69.19M | 61.42M | 66.65M | 66.58M | 66.37M | 56.68M | 57.86M | 54.77M | 54.21M | 47.34M | 52.32M | 52.08M | 51.91M | 46.57M | 49.38M | 44.02M | 39.86M | 38.82M |
| Weighted Average Shares Outstanding Diluted | 83.50M | 78.57M | 69.19M | 61.42M | 66.65M | 66.58M | 66.37M | 56.68M | 57.86M | 54.77M | 54.21M | 47.34M | 52.32M | 52.08M | 51.91M | 46.57M | 49.38M | 44.02M | 39.86M | 38.82M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $74.46M | $146.59M | $105.95M | $182.52M | $59.50M |
| Short Term Investments | $346.21M | $436.80M | $289.71M | $293.78M | $109.06M |
| Cash and Short Term Investments | $420.67M | $583.39M | $395.65M | $476.30M | $168.56M |
| Net Receivables | $4.92M | $2.94M | $3.06M | $2.95M | $2.96M |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $8.08M | $6.28M | $3.27M | $4.49M | $1.76M |
| Total Current Assets | $433.67M | $592.60M | $403.98M | $483.75M | $174.25M |
| Property Plant Equipment Net | $52.35M | $52.35M | $55.58M | $57.72M | $58.21M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $1.64M | $1.64M | $1.64M | $1.64M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.70M | $- | $- | $- | $- |
| Total Non-Current Assets | $54.05M | $53.99M | $57.22M | $59.35M | $59.85M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $487.72M | $646.59M | $461.19M | $543.10M | $234.10M |
| Account Payables | $2.58M | $5.36M | $3.73M | $2.35M | $3.43M |
| Short Term Debt | $7.76M | $3.76M | $7.26M | $6.91M | $6.57M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $21.71M | $12.07M | $8.22M | $4.85M |
| Other Current Liabilities | $30.10M | $24.70M | $9.76M | $5.28M | $1.87M |
| Total Current Liabilities | $40.44M | $33.83M | $20.76M | $14.55M | $11.87M |
| Long Term Debt | $71.99M | $57.00M | $29.21M | $29.82M | $38.51M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $786.00K | $472.00K | $- | $- | $- |
| Total Non-Current Liabilities | $72.78M | $57.47M | $29.21M | $29.82M | $38.51M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $113.21M | $91.30M | $49.96M | $44.37M | $50.38M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $61.00K | $57.00K | $47.00K | $47.00K | $37.00K |
| Retained Earnings | $-701.28M | $-485.49M | $-311.20M | $-193.17M | $-112.30M |
| Accumulated Other Comprehensive Income Loss | $4.86M | $5.73M | $-973.00K | $-394.00K | $-982.00K |
| Other Total Stockholders Equity | $1.07B | $1.03B | $723.36M | $692.24M | $296.96M |
| Total Stockholders Equity | $374.51M | $555.29M | $411.23M | $498.73M | $183.72M |
| Total Equity | $374.51M | $555.29M | $411.23M | $498.73M | $183.72M |
| Total Liabilities and Stockholders Equity | $487.72M | $646.59M | $461.19M | $543.10M | $234.10M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $487.72M | $646.59M | $461.19M | $543.10M | $234.10M |
| Total Investments | $346.21M | $436.80M | $289.71M | $293.78M | $109.06M |
| Total Debt | $75.87M | $60.76M | $32.84M | $33.28M | $41.79M |
| Net Debt | $1.41M | $-85.83M | $-73.11M | $-149.24M | $-17.71M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $172.25M | $113.49M | $151.66M | $74.46M | $97.67M | $76.00M | $106.48M | $146.59M | $206.67M | $88.93M | $112.25M | $105.95M | $132.28M | $159.97M | $192.53M | $182.52M | $324.48M | $43.33M | $104.80M | $59.50M |
| Short Term Investments | $364.29M | $318.56M | $317.47M | $346.21M | $368.68M | $420.76M | $432.62M | $436.80M | $409.71M | $282.89M | $282.84M | $289.71M | $287.90M | $275.80M | $265.80M | $293.78M | $168.80M | $201.32M | $156.96M | $109.06M |
| Cash and Short Term Investments | $536.54M | $432.06M | $469.12M | $420.67M | $466.35M | $496.76M | $539.10M | $583.39M | $616.37M | $371.82M | $395.08M | $395.65M | $420.17M | $435.77M | $458.33M | $476.30M | $493.27M | $244.65M | $261.76M | $168.56M |
| Net Receivables | $3.07M | $832.00K | $4.93M | $4.92M | $4.29M | $2.90M | $3.05M | $2.94M | $2.00M | $2.59M | $2.83M | $3.06M | $2.21M | $2.89M | $2.97M | $2.95M | $2.12M | $3.08M | $2.95M | $2.96M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.83M | $- | $- | $- | $- | $- | $-2.12M | $-3.08M | $-2.95M | $-2.96M |
| Other Current Assets | $7.97M | $9.74M | $6.26M | $8.08M | $8.52M | $8.51M | $7.89M | $6.28M | $5.59M | $4.98M | $4.04M | $3.27M | $3.51M | $5.73M | $1.86M | $4.49M | $4.04M | $4.69M | $3.03M | $2.73M |
| Total Current Assets | $547.58M | $442.63M | $480.32M | $433.67M | $479.16M | $508.18M | $550.04M | $592.60M | $623.96M | $379.39M | $401.95M | $403.98M | $427.80M | $444.38M | $464.56M | $483.75M | $499.43M | $252.41M | $267.74M | $174.25M |
| Property Plant Equipment Net | $17.74M | $53.03M | $52.51M | $52.35M | $52.13M | $51.78M | $51.81M | $52.35M | $52.95M | $53.77M | $55.02M | $55.58M | $55.85M | $55.98M | $56.74M | $57.72M | $58.13M | $58.73M | $59.53M | $58.21M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $1.70M | $1.64M | $2.44M | $2.04M | $1.64M | $1.64M | $2.93M | $2.46M | $1.64M | $1.64M | $3.10M | $2.42M | $1.64M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $38.31M | $2.54M | $2.14M | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.64M | $3.10M | $2.31M | $1.64M |
| Total Non-Current Assets | $56.05M | $55.57M | $54.65M | $54.05M | $53.77M | $54.22M | $53.85M | $53.99M | $54.59M | $56.70M | $57.48M | $57.22M | $57.49M | $59.08M | $59.16M | $59.35M | $59.77M | $61.83M | $61.84M | $59.85M |
| Other Assets | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $-0 | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- |
| Total Assets | $603.63M | $498.20M | $534.97M | $487.72M | $532.93M | $562.40M | $603.89M | $646.59M | $678.55M | $436.10M | $459.43M | $461.19M | $485.28M | $503.46M | $523.72M | $543.10M | $559.20M | $314.24M | $329.58M | $234.10M |
| Account Payables | $7.19M | $8.41M | $864.00K | $2.58M | $3.90M | $4.37M | $4.88M | $5.36M | $3.65M | $4.00M | $4.48M | $3.73M | $3.92M | $3.15M | $2.38M | $2.35M | $2.35M | $2.37M | $3.48M | $3.43M |
| Short Term Debt | $3.94M | $3.96M | $7.80M | $7.76M | $7.72M | $3.82M | $7.59M | $3.76M | $7.32M | $7.20M | $7.23M | $7.26M | $7.23M | $6.98M | $6.96M | $6.91M | $6.87M | $6.69M | $6.52M | $6.57M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $30.65M | $27.32M | $27.76M | $20.57M | $21.71M | $18.01M | $13.42M | $11.17M | $12.07M | $9.83M | $9.09M | $8.39M | $8.22M | $6.71M | $6.27M | $4.56M | $4.85M |
| Other Current Liabilities | $36.76M | $31.42M | $27.01M | $30.10M | $27.02M | $31.65M | $19.77M | $24.70M | $15.50M | $12.34M | $8.60M | $9.76M | $7.14M | $6.50M | $5.71M | $5.28M | $3.80M | $3.90M | $1.88M | $1.87M |
| Total Current Liabilities | $47.89M | $43.79M | $35.68M | $40.44M | $38.65M | $39.83M | $32.24M | $33.83M | $26.46M | $23.54M | $20.31M | $20.76M | $18.29M | $16.64M | $15.05M | $14.55M | $13.02M | $12.96M | $11.88M | $11.87M |
| Long Term Debt | $26.14M | $72.17M | $72.05M | $71.99M | $71.95M | $56.92M | $57.04M | $57.00M | $56.74M | $28.49M | $28.85M | $29.21M | $29.48M | $29.42M | $29.65M | $29.82M | $29.98M | $39.89M | $39.89M | $38.51M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $47.23M | $786.00K | $786.00K | $786.00K | $793.00K | $472.00K | $578.00K | $472.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $73.36M | $72.95M | $72.83M | $72.78M | $72.74M | $57.39M | $57.62M | $57.47M | $56.74M | $28.49M | $28.85M | $29.21M | $29.48M | $29.42M | $29.65M | $29.82M | $29.98M | $39.89M | $39.89M | $38.51M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- |
| Total Liabilities | $121.25M | $116.74M | $108.51M | $113.21M | $111.39M | $97.23M | $89.86M | $91.30M | $83.20M | $52.02M | $49.16M | $49.96M | $47.77M | $46.05M | $44.70M | $44.37M | $43.00M | $52.85M | $51.77M | $50.38M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $77.00K | $68.00K | $68.00K | $61.00K | $61.00K | $59.00K | $57.00K | $57.00K | $57.00K | $50.00K | $49.00K | $47.00K | $47.00K | $47.00K | $47.00K | $47.00K | $46.00K | $40.00K | $40.00K | $37.00K |
| Retained Earnings | $-874.45M | $-808.11M | $-755.05M | $-701.28M | $-646.21M | $-595.09M | $-535.04M | $-485.49M | $-436.25M | $-396.56M | $-353.46M | $-311.20M | $-279.51M | $-249.83M | $-220.48M | $-193.17M | $-171.67M | $-149.89M | $-129.79M | $-112.30M |
| Accumulated Other Comprehensive Income Loss | $6.16M | $3.63M | $4.32M | $4.86M | $4.73M | $5.49M | $3.97M | $5.73M | $3.74M | $2.93M | $520.00K | $-973.00K | $-181.00K | $9.00K | $-210.00K | $-394.00K | $-116.00K | $-611.00K | $-1.19M | $-982.00K |
| Other Total Stockholders Equity | $1.35B | $1.19B | $1.18B | $1.07B | $1.06B | $1.05B | $1.05B | $1.03B | $1.03B | $777.65M | $763.15M | $723.36M | $717.15M | $707.19M | $699.67M | $692.24M | $687.93M | $411.85M | $408.75M | $296.96M |
| Total Stockholders Equity | $482.37M | $381.46M | $426.45M | $374.51M | $421.54M | $465.17M | $514.03M | $555.29M | $595.35M | $384.07M | $410.26M | $411.23M | $437.51M | $457.41M | $479.02M | $498.73M | $516.20M | $261.39M | $277.81M | $183.72M |
| Total Equity | $482.37M | $381.46M | $426.45M | $374.51M | $421.54M | $465.17M | $514.03M | $555.29M | $595.35M | $384.07M | $410.26M | $411.23M | $437.51M | $457.41M | $479.02M | $498.73M | $516.20M | $261.39M | $277.81M | $183.72M |
| Total Liabilities and Stockholders Equity | $603.63M | $498.20M | $534.97M | $487.72M | $532.93M | $562.40M | $603.89M | $646.59M | $678.55M | $436.10M | $459.43M | $461.19M | $485.28M | $503.46M | $523.72M | $543.10M | $559.20M | $314.24M | $329.58M | $234.10M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $603.63M | $498.20M | $534.97M | $487.72M | $532.93M | $562.40M | $603.89M | $646.59M | $678.55M | $436.10M | $459.43M | $461.19M | $485.28M | $503.46M | $523.72M | $543.10M | $559.20M | $314.24M | $329.58M | $234.10M |
| Total Investments | $364.29M | $318.56M | $317.47M | $346.21M | $368.68M | $420.76M | $432.62M | $436.80M | $409.71M | $282.89M | $282.84M | $289.71M | $287.90M | $275.80M | $265.80M | $293.78M | $168.80M | $201.32M | $156.96M | $109.06M |
| Total Debt | $30.08M | $76.12M | $75.95M | $75.87M | $75.81M | $60.74M | $60.84M | $60.76M | $60.40M | $32.09M | $32.47M | $32.84M | $33.10M | $32.91M | $33.13M | $33.28M | $33.42M | $43.23M | $43.15M | $41.79M |
| Net Debt | $-142.16M | $-37.37M | $-75.71M | $1.41M | $-21.86M | $-15.26M | $-45.64M | $-85.83M | $-146.27M | $-56.84M | $-79.78M | $-73.11M | $-99.18M | $-127.06M | $-159.40M | $-149.24M | $-291.06M | $-91.00K | $-61.65M | $-17.71M |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-215.79M | $-174.28M | $-118.04M | $-80.87M | $-52.62M |
| Depreciation and Amortization | $2.65M | $2.45M | $2.15M | $1.71M | $533.00K |
| Deferred Income Tax | $- | $38.00K | $- | $2.29M | $-945.00K |
| Stock Based Compensation | $34.12M | $28.13M | $24.25M | $11.79M | $7.74M |
| Change in Working Capital | $5.48M | $15.12M | $7.24M | $3.51M | $-15.41M |
| Accounts Receivables | $- | $-61.00K | $-247.00K | $325.00K | $-628.00K |
| Inventory | $- | $61.00K | $247.00K | $-325.00K | $628.00K |
| Accounts Payables | $-2.79M | $1.98M | $1.12M | $-1.03M | $-3.82M |
| Other Working Capital | $8.28M | $13.14M | $6.12M | $4.54M | $-11.59M |
| Other Non Cash Items | $-11.94M | $494.00K | $2.22M | $181.00K | $156.00K |
| Net Cash Provided by Operating Activities | $-185.47M | $-128.05M | $-82.18M | $-61.39M | $-60.55M |
| Investments in Property Plant and Equipment | $-5.66M | $-2.27M | $-2.34M | $-2.39M | $-6.54M |
| Acquisitions Net | $- | $140.23K | $-530 | $186.38K | $-1.31K |
| Purchases of Investments | $-489.52M | $-583.41M | $-255.72M | $-392.43M | $-149.68M |
| Sales Maturities of Investments | $592.38M | $443.18M | $256.25M | $206.05M | $150.99M |
| Other Investing Activities | $- | $-140.23K | $530 | $-186.38K | $1.31K |
| Net Cash Used for Investing Activities | $97.20M | $-142.50M | $-1.81M | $-188.78M | $-5.23M |
| Debt Repayment | $14.52M | $27.79M | $-264.00K | $-10.14M | $9.94M |
| Common Stock Issued | $1.76M | $187.29M | $6.86M | $286.11M | $61.88M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.76M | $96.22M | $6.86M | $96.50M | $28.34M |
| Net Cash Used Provided by Financing Activities | $16.28M | $311.30M | $6.60M | $372.46M | $100.17M |
| Effect of Forex Changes on Cash | $-86.00K | $-109.00K | $818.00K | $721.00K | $-135.00K |
| Net Change in Cash | $-72.07M | $40.64M | $-76.57M | $123.02M | $34.25M |
| Cash at End of Period | $76.16M | $148.23M | $107.58M | $184.15M | $61.14M |
| Cash at Beginning of Period | $148.23M | $107.58M | $184.15M | $61.14M | $26.89M |
| Operating Cash Flow | $-185.47M | $-128.05M | $-82.18M | $-61.39M | $-60.55M |
| Capital Expenditure | $-5.66M | $-2.27M | $-2.34M | $-2.39M | $-6.54M |
| Free Cash Flow | $-191.13M | $-130.32M | $-84.52M | $-63.78M | $-67.09M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-66.34M | $-53.05M | $-53.77M | $-55.08M | $-51.12M | $-60.04M | $-49.55M | $-49.24M | $-39.69M | $-43.10M | $-42.25M | $-31.70M | $-29.67M | $-29.36M | $-27.31M | $-21.50M | $-21.78M | $-20.09M | $-17.49M | $-15.79M |
| Depreciation and Amortization | $-800.00K | $-4.29M | $736.00K | $705.00K | $675.00K | $654.00K | $621.00K | $528.00K | $682.00K | $617.00K | $620.00K | $549.00K | $548.00K | $532.00K | $518.00K | $494.00K | $401.00K | $425.00K | $391.00K | $342.00K |
| Deferred Income Tax | $- | $- | $- | $10.82M | $-4.40M | $-957.00K | $-5.46M | $1.82M | $- | $- | $- | $- | $- | $- | $- | $- | $1.34M | $318.00K | $91.00K | $-46.00K |
| Stock Based Compensation | $8.64M | $8.65M | $9.47M | $7.92M | $8.24M | $9.12M | $8.85M | $6.92M | $7.02M | $6.99M | $7.19M | $5.77M | $5.92M | $6.31M | $6.25M | $3.47M | $3.05M | $2.80M | $2.47M | $1.81M |
| Change in Working Capital | $- | $2.79M | $-2.79M | $2.18M | $-791.00K | $7.39M | $-3.29M | $6.91M | $4.78M | $2.69M | $741.00K | $2.39M | $4.35M | $-1.08M | $1.57M | $870.00K | $3.94M | $-691.00K | $-610.00K | $2.36M |
| Accounts Receivables | $- | $- | $- | $-667.00K | $-414.00K | $-442.00K | $-393.00K | $-873.00K | $2.23M | $-567.00K | $-850.00K | $-947.00K | $2.21M | $-725.00K | $-788.00K | $-753.00K | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $-1.25M | $414.00K | $442.00K | $393.00K | $873.00K | $-2.23M | $567.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.15M | $7.46M | $-1.61M | $-1.29M | $-476.00K | $-213.00K | $-816.00K | $1.62M | $-341.00K | $-197.00K | $895.00K | $-75.00K | $443.00K | $684.00K | $66.00K | $-13.00K | $180.00K | $-974.00K | $-224.00K | $-1.24M |
| Other Working Capital | $5.64M | $-4.67M | $-1.18M | $4.14M | $-315.00K | $7.60M | $-2.48M | $5.29M | $5.12M | $2.88M | $-154.00K | $2.46M | $3.91M | $-1.76M | $1.50M | $883.00K | $3.76M | $283.00K | $-386.00K | $3.60M |
| Other Non Cash Items | $7.79M | $7.26M | $-2.81M | $375.00K | $273.00K | $256.00K | $257.00K | $259.00K | $-1.39M | $-404.00K | $1.14M | $428.00K | $508.00K | $626.00K | $658.00K | $535.00K | $1.40M | $381.00K | $154.00K | $16.00K |
| Net Cash Provided by Operating Activities | $-50.71M | $-38.64M | $-49.17M | $-46.17M | $-47.12M | $-43.59M | $-48.59M | $-32.80M | $-28.59M | $-33.21M | $-33.45M | $-22.56M | $-18.35M | $-22.96M | $-18.31M | $-16.13M | $-12.99M | $-17.18M | $-15.09M | $-11.26M |
| Investments in Property Plant and Equipment | $-1.80M | $-2.08M | $-1.67M | $-1.74M | $-1.72M | $-1.75M | $-449.00K | $-251.00K | $-555.00K | $-396.00K | $-1.07M | $-1.15M | $-465.00K | $-428.00K | $-291.00K | $-770.00K | $-615.00K | $-75.00K | $-932.00K | $-1.34M |
| Acquisitions Net | $- | $- | $- | $77.92K | $-55.67K | $-14.44K | $-7.81K | $22.50K | $124.55K | $-432 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-137.02M | $-89.46M | $-105.47M | $-108.40M | $-99.87M | $-111.92M | $-169.33M | $-149.50M | $-240.23M | $-133.07M | $-60.62M | $-63.17M | $-81.19M | $-79.12M | $-32.23M | $-167.41M | $-28.49M | $-70.72M | $-125.81M | $-30.07M |
| Sales Maturities of Investments | $92.50M | $92.00M | $136.91M | $133.34M | $155.54M | $126.35M | $177.14M | $127.00M | $115.68M | $133.50M | $67.00M | $60.00M | $68.23M | $68.50M | $59.52M | $41.90M | $60.53M | $26.00M | $77.62M | $39.25M |
| Other Investing Activities | $- | $- | $- | $24.94M | $55.67K | $14.44K | $7.81K | $-22.50K | $-124.55K | $432 | $6.38M | $-3.17M | $-12.96M | $-10.62M | $27.28M | $-125.50M | $32.04M | $-44.72M | $-48.19M | $9.18M |
| Net Cash Used for Investing Activities | $-46.32M | $458.00K | $29.77M | $23.20M | $53.96M | $12.68M | $7.36M | $-22.75M | $-125.10M | $36.00K | $5.32M | $-4.33M | $-13.42M | $-11.05M | $26.99M | $-126.27M | $31.42M | $-44.80M | $-49.13M | $7.84M |
| Debt Repayment | $-159.00K | $-143.00K | $-134.00K | $-131.00K | $14.87M | $-113.00K | $-104.00K | $-1.95M | $29.90M | $-86.00K | $-77.00K | $-76.00K | $-74.00K | $-61.00K | $-53.00K | $-53.00K | $-9.95M | $-110.00K | $-32.00K | $-37.00K |
| Common Stock Issued | $204.53M | $-48.57M | $48.20M | $1.00K | $-2.00K | $551.00K | $1.21M | $-248.00K | $150.10M | $6.40M | $31.04M | $435.00K | $4.04M | $1.21M | $1.17M | $838.00K | $211.22M | $-316.00K | $75.20M | $- |
| Common Stock Repurchased | $- | $- | $- | $2 | $-2 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-25.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-48.44M | $104.00K | $48.57M | $1.00K | $-2.00K | $551.00K | $1.21M | $2.12M | $91.43M | $1.11M | $1.56M | $435.00K | $4.04M | $1.21M | $1.17M | $838.00K | $60.92M | $391.00K | $34.35M | $71.00K |
| Net Cash Used Provided by Financing Activities | $155.93M | $-39.00K | $96.64M | $-130.00K | $14.87M | $438.00K | $1.10M | $-77.00K | $271.44M | $7.42M | $32.52M | $359.00K | $3.97M | $1.15M | $1.12M | $785.00K | $262.20M | $-35.00K | $109.51M | $34.00K |
| Effect of Forex Changes on Cash | $-151.00K | $61.00K | $-35.00K | $-56.00K | $-27.00K | $-16.00K | $13.00K | $-4.45M | $-8.00K | $2.44M | $1.92M | $197.00K | $105.00K | $304.00K | $212.00K | $-341.00K | $522.00K | $541.00K | $-1.00K | $-115.00K |
| Net Change in Cash | $58.75M | $-38.16M | $77.20M | $-23.15M | $21.68M | $-30.48M | $-40.11M | $-60.08M | $117.74M | $-23.32M | $6.30M | $-26.33M | $-27.69M | $-32.56M | $10.01M | $-141.96M | $281.15M | $-61.47M | $45.30M | $-3.50M |
| Cash at End of Period | $173.94M | $115.20M | $153.36M | $76.16M | $99.31M | $77.63M | $108.12M | $148.23M | $208.30M | $90.57M | $113.88M | $107.58M | $133.91M | $161.60M | $194.16M | $184.15M | $326.11M | $44.96M | $106.43M | $61.14M |
| Cash at Beginning of Period | $115.20M | $153.36M | $76.16M | $99.31M | $77.63M | $108.12M | $148.23M | $208.30M | $90.57M | $113.88M | $107.58M | $133.91M | $161.60M | $194.16M | $184.15M | $326.11M | $44.96M | $106.43M | $61.14M | $64.64M |
| Operating Cash Flow | $-50.71M | $-38.64M | $-49.17M | $-46.17M | $-47.12M | $-43.59M | $-48.59M | $-32.80M | $-28.59M | $-33.21M | $-33.45M | $-22.56M | $-18.35M | $-22.96M | $-18.31M | $-16.13M | $-12.99M | $-17.18M | $-15.09M | $-11.26M |
| Capital Expenditure | $-1.80M | $-2.08M | $-1.67M | $-1.74M | $-1.72M | $-1.75M | $-449.00K | $-251.00K | $-555.00K | $-396.00K | $-1.07M | $-1.15M | $-465.00K | $-428.00K | $-291.00K | $-770.00K | $-615.00K | $-75.00K | $-932.00K | $-1.34M |
| Free Cash Flow | $-52.51M | $-40.72M | $-50.84M | $-47.91M | $-48.84M | $-45.34M | $-49.04M | $-33.05M | $-29.14M | $-33.61M | $-34.52M | $-23.71M | $-18.81M | $-23.39M | $-18.61M | $-16.90M | $-13.61M | $-17.25M | $-16.02M | $-12.60M |
Replimune Group Dividends
Explore Replimune Group's dividend history, including dividend yield, payout ratio, and historical payments.
Replimune Group News
Read the latest news about Replimune Group, including recent articles, headlines, and updates.
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
Replimune: A Misunderstood Contender In Oncolytics
Replimune Group's solid cash position and strategic focus on niche oncology markets position it for potential success, despite market volatility and past trial setbacks. The company's RP1 and RP2 platforms target unmet needs in melanoma and other cancers, with promising data and regulatory momentum supporting their potential. The FDA's Priority Review and Breakthrough Therapy designations for RP1 underscore its potential to reshape second-line melanoma treatment and expedite market entry.
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) plus nivolumab in advanced melanoma is enrolling Enrolled first patients in trials evaluating RP2 for the treatment of metastatic uveal melanoma and hepatocellular carcinoma WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2024 and provided a business update.
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT.
Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch
Replimune has submitted its BLA of RP1 + Opdivo for the treatment of advanced melanoma patients previously treated with an anti-PD1 containing regimen. The phase 3 confirmatory IGNYTE-3 study is underway to prove yet again that RP1 + Opdivo is able to help these patients with advanced melanoma and to keep the drug marketed. The global melanoma therapeutics market size is projected to reach $17.93 billion by 2034.
Replimune Announces Pricing of Upsized Public Offering
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 shares of its common stock at a public offering price of $13.00 per share. In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 3,846,184 shares of its common stock at a purchase price of $12.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $140 million, before deducting the underwriting discounts and commissions and offering expenses payable by Replimune. All securities in the offering are being offered by Replimune. In addition, Replimune has granted the underwriter a 30-day option to purchase up to an additional 1,615,377 shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on November 27, 2024, subject to the satisfaction of customary closing conditions.
Replimune Announces Proposed Public Offering
WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriter a 30-day option to purchase up to an additional $18.75 million of securities from Replimune at the public offering price, less the underwriting discounts and commissions.
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the Accelerated Approval pathway. The Company also announced that the FDA has granted Breakthrough Therapy designation to RP1 in combination with nivolumab in the same setting.
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, and kinetics
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 192,770 shares in Replimune Group Inc (REPL, Financial), a clinical-stage biotechnology company. This move reduced Morgan Stanley's holding by 11.11%, leaving the firm with a total of 1,542,884 shares.
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1
Replimune: Strong Data In A Highly Differentiated Space
Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, demonstrated a 29.4% ORR in phase 1 trials, with durable responses in difficult-to-treat tumors. Despite competitive challenges and a failed CSCC trial, Replimune's cash runway supports its accelerated approval and phase 3 trials, making it an attractive investment.
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanoma Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanoma
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the following two conferences:
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET.
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass.
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data from IGNYTE trial -- -- RP2 as monotherapy and in combination with nivolumab in uveal melanoma demonstrates overall response rate of nearly 30 percent; planning for registration-directed trial underway --
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024.
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
WOBURN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2024 and provided a business update.
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for REPL.